Gland Pharma Limited (BSE: 543245 I NSE: GLAND), a generic injectable-focused pharmaceutical company, today announced its financial results for the Second quarter (Q2FY25) ended on September 30th, 2024. Financial Highlights Q2 FY25 (July 2024 to September 2024) • Consolidated revenue increased 2% year-over-year to INR 14,058 million. • Consolidated EBITDA decreased
Axis Securities Report Highlights Positive Trends for Q2 FY25 The Indian pharmaceutical industry is poised for a robust year, with revenue growth projected at 8.5% year-on-year (YoY) for the second quarter of FY25, driven primarily by domestic formulations and strategic niche launches in the US market.
Azad Moopen, Founder Chairman and Managing Director, Aster DM Healthcare “A nation’s culture resides in the hearts and soul of its people,” said Mahatma Gandhi, the father of the Indian nation and the world icon of peace. Nothing would resonate better with the millions of
Rana was earlier with Sun Pharma Consumer Healthcare for 6 years as Head of Marketing & eCommerce Former Sun Pharma Consumer Healthcare senior executive Tarundeep Singh Rana has joined Zydus Healthcare Limited as the Chief Marketing Officer. He was with Sun Consumer Healthcare for 6 years
Healthy Growth in FDI and Digital Initiatives further fueling growth of Domestic Pharma Industry India’s $42 billion pharmaceutical sector is heavily dependent on China for key active pharmaceutical ingredients or API — chemicals that are responsible for the therapeutic effect of drugs. Various estimates put India’s dependence
In its 2022 annual recognition prizes, the American Gastroenterological Association (AGA) announced Dr. Reddy’s name for the award. Founded in 1897, the American Gastroenterological Association (AGA) with more than 16,000 members from around the globe involved in advancement of gastroenterology, is world’s most reputed scientific body
